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INTRODUCTION
The centrosome plays an essential role in the control of genomic stability through the establishment of the bipolar mitotic spindle and equal segregation of chromosomes during cell division . The centrosome is duplicated once, and only once, during a normal cell cycle to give rise to two centrosomes that function as the spindles poles of the dividing cell (Kellog 1989) . In order to maintain the integrity of the genome, centrosome duplication is strictly coordinated with DNA replication during cell cycle progression , 2004 , Sluder et al. 2000 . Centrosome homeostasis results from the complex interaction of oncogenes and tumor suppressors operating at level of the G1/S and G2/M cell cycle checkpoints. In the development of cancer, deregulation of the centrosome duplication cycle leads to centrosome amplification and abnormal multipolar mitoses, and consequent chromosome missegregation. This, in turn, results in an increase in the rate of chromosomal instability and phenotypic diversity in the cancer cells, thereby promoting tumor progression, chemoresistance, and poor outcome.
The aim of our research is to elucidate the mechanisms by which the normal regulatory pathways coordinating centrosome duplication with cell cycle events become uncoupled. Since negative (tumor suppressors) and positive (oncogenes) regulators of cell cycle progression can also regulate centrosome duplication, we propose that in breast cancer, alterations in growth factor signaling pathways, and/or inactivation of the p53 pathway act to deregulate G1/S and/or G2/M cell cycle checkpoints. Centrosome amplification may represent an early event in breast cancer development, while the degree of amplification may also increase during tumor progression accelerating the rate of chromosomal instability and aggressiveness. These studies will have an important impact in basic and clinical oncology for two reasons: first, they will help to define the molecular mechanisms leading to centrosome amplification in breast cancer; second, they will clarify if centrosome amplification represents a driving force in selecting hormoneindependent and chemoresistant clones in breast cancer and its potential role as a new suitable marker of tumor aggressiveness.
KEY RESEARCH ACCOMPLISHMENTS
Specific aim #1: Determine the role of 17-B estradiol and EGF growth factor receptor activation in the regulation of centrosome duplication.
Breast cancer is a hormone-dependent disease: estrogens play an essential role in the onset of breast cancer, however, the hormone-dependent phenotype is commonly lost during tumor progression. The EGF growth factor pathway also plays a key role not only in the development of breast cancer but also in the progression of the disease since advanced breast cancers often over-express the EGF receptor and show an hormoneindependent and chemoresistant phenotype.
The goal of this first aim is to determine the role that 17-B estradiol and EGF growth factor pathways play in the regulation of centrosome duplication. We propose to develop and validate an in vitro model system for centrosome duplication that can be used to dissect the signaling events that are required for the development of centrosome amplification in breast cancer.
Our results to date demonstrate that in the MCF-7 breast cancer cell line, 17-B estradiol and EGF stimulate centrosome duplication and this process is well coordinated with the expression of key cell cycle regulators (cyclin D, E, A, B,) and with the phosphorylation status of the retinoblastoma tumor suppressor. Furthermore, in order to understand if abrogation of the p53 pathway may deregulate the centrosome duplication cycle in the MCF-7 cells stimulated with mitogens, we generated an MCF-7 cell line stable expressing a p53 dominant-negative construct (MCF-7Dnp53) to mask the function of the wild-type p53.
Interestingly, the MCF-7Dnp53 stimulated with estradiol and EGF exhibited a deregulation of the cell cycle regulators that was associated with an amplified centrosome phenotype, suggesting that development of centrosome amplification in breast cancer requires not only the acceleration of cell cycle progression through mitogens but also the inactivation of the p53 pathway with important consequences on the G1/S timing progression. These results suggest a model of multi-step neoplastic transformation where estrogens and growth factors initiate the development of breast cancer and the consequent abrogation of the p53 pathway during tumor progression promotes the development of centrosome amplification leading to genomic instability, chemoresistance and poor outcome.
A manuscript describing these experiments and results is currently in preparation.
Specific aim #2: Determine the relationship between cell cycle checkpoints and centrosome amplification.
The goal of this second aim is to determine the molecular mechanisms linking inactivation of the G1/S and G2/M cell cycle checkpoints to centrosome amplification in breast cancer. We have focused on the role of the G1/S checkpoint in the control of centrosome homeostasis. Our results demonstrate that induction of genotoxic stress induces centrosome amplification in breast cancer cell lines with an abrogated G1/S cell cycle checkpoint and have recently been published in Oncogene (D'Assoro et al, 2004) .
We used breast cancer cell lines with different p53 backgrounds to investigate the relationship between DNA damage, G I/S cell cycle checkpoint integrity, and the development of centrosome amplification. Introduction of DNA damage in the MCF-7 cell line by treatment with hydroxyurea (HU) or daunorubicin (DR) resulted in the arrest of both GI/S cell cycle progression and centriole duplication. In these cells, which carry functional p53, HU treatment also led to nuclear accumulation of p53 and p21WAF1, retinoblastoma hypophosphorylation, and downregulation of cyclin A. MCF-7 cells carrying a recombinant dominant-negative p53 mutant (vMCF-7DNp53) exhibited a shortened G 1 phase of the cell cycle and retained a normal centrosome phenotype. However, these cells developed amplified centrosomes following HU treatment. The MDA-MB 231 cell line, which carries mutant p53 at both alleles, showed amplified centrosomes at the outset, and developed a hyperamplified centrosome phenotype following HU treatment. In cells carrying defective p53, the development of centrosome amplification also occurred following treatment with another DNA damaging agent, DR. Taken together, these findings demonstrate that loss of p53 function alone is not sufficient to drive centrosome amplification, but plays a critical role in this process following DNA damage through abrogation of the G 1/S cell cycle checkpoint. Interestingly, we were able to reactivate the Gl/S checkpoint and revert the centrosome phenotype in the MDA-MB 231 cell line following genotoxic stress by using a potent cdk inhibitor, Roscovitine.
The novelty of these results demonstrate for the first time a clear relationship between DNA damage, abrogation of the G1/S checkpoint and the development of centrosome amplification. These observations have important clinical implications regarding the management of breast cancer patients: first, they suggest that breast cancers with compromised p53 function may develop centrosome amplification and consequent chromosomal instability following treatment with genotoxic anticancer drugs. Second, to overcome the complications associated with centrosome amplification for this subset of breast cancer patients, treatment with cdk inhibitors in combination with anticancer genotoxic drugs may provide a new attractive therapeutic approach.
CONCLUSIONS
Our studies suggest that the development and progression of breast cancer is a complex process involving the role of estrogens, growth factor signaling pathways and abrogation of the p53 protein leading to an inactivation of the G 1/S cell cycle checkpoint. In turn, the abrogation of the G 1/S checkpoint activity leads to the development of centrosome amplification that may represents the driven force to promote genomic instability and phenotypic heterogeneity in breast cancer. The development of these pathological processes may confer to the tumor cells high metastatic potential and chemoresistant properties with catastrophic consequences for breast cancer patients. We also suggest that the further characterization of the mechanisms leading to centrosome amplification in breast cancer proposed in this grant will help to define in the centrosome a suitable marker of tumor aggressiveness and a new target for breast cancer treatment, Centrosome amplification plays a key role in the origin of Introduction chromosomal instability during cancer development and progression. In this study, breast cancer cell lines with
The progression of aggressive breast cancer is chardifferent p53 backgrounds were used to investigate the acterized by genomic instability leading to multiple relationship between genotoxic stress, Gl/S cell cycle genetic defects, phenotypic diversity, chernoresistance, checkpoint integrity, and the development of centrosome and poor outcome (Lengauer et al., 1998; Loeb, 2001 ). amplification. Introduction of DNA damage in the MCF-7
An imbalance between oncogene and tumor suppressor cell line by treatment with hydroxyurea (HU) or activities plays an important role in the onset of breast daunorubicin (DR) resulted in the arrest of both G,/S cancer through the inactivation of Gl/S and/or G 2 /M cell cycle progression and centriole duplication. In these checkpoints, which normally ensure the orderly progrescells, which carry functional p53, HU treatment also led sion of cell cycle events (Hartwell and Weinert, 1989) . In to nuclear accumulation of p53 and p21wA"I, retinoblasnormal cells, checkpoint activation in response to DNA toma hypophosphorylation, and downregulation of cyclin damage is mediated by p53 through upregulation of its A. MCF-7 cells carrying a recombinant dominantdownstream targets, and consequent cell cycle arrest negative p53 mutant (vMCF-7DNp5
3 ) exhibited a shortened (Wang et al., 1999; Jin and Levine, 2001 ; Taylor and G 1 phase of the cell cycle and retained a normal Stark, 2001) . Recently, the centrosome has been centrosome phenotype. However, these cells developed implicated in the pathogenesis of cancer through the amplified centrosomes following HU treatment. The development of multipolar mitotic spindles leading to MDA-MB 231 cell line, which carries mutant p53 at chromosomal instability and clonal heterogeneity both alleles, showed amplified centrosomes at the outset, (Brinkley, 2001; D'Assoro et al., 2002b) . The centroand developed a hyperamplified centrosome phenotype some is the major microtubule-organizing center of the following HU treatment. In cells carrying defective p53, cell and is duplicated once during a normal cell cycle to the development of centrosome amplification also ocgive rise to two centrosomes that function as the spindle curred following treatment with another DNA damaging poles during mitosis (Kirschner and Mitchison, 1986 ; agent, DR. Taken together, these findings demonstrate Kellogg, 1989; Palazzo, 2003) . Therefore, tight coordithat loss of p53 function alone is not sufficient to drive nation between the centrosome duplication and DNA centrosome amplification, but plays a critical role in this replication cycles is essential to ensure equal segregation process following DNA damage through abrogation of the of sister chromatids during cell division (Sluder and Gl/S cell cycle checkpoint. Furthermore, these studies Hinchcliffe, 2000) . However, centrosome duplication is have important clinical implications because they suggest not strictly dependent on DNA replication since the that breast cancers with compromised p53 function may centrosome and DNA cycles can be uncoupled (Balczon develop centrosome amplification and consequent chroet al., 1995 coordinating centrosome duplication with cell cycle retinoblastorma events. In mouse model studies, loss of p53 by gene targeting and gain-of-function p53 mutations resulted in the development of centrosome amplification and aberrant mitoses (Fukasawa et al., 1996; Fry et al.. 1999; Murphy and Rosen, 2000; Tarapore et a(.. 2001 , retinoblastoma and consequent activation of the E2F transcription factor (Angus et al., 2002) . A role for p53 and retinoblastoma (Rb) in this process is also suggested by studies where inactivation of these tumor suppressors after infection with high-risk human papillomaviruses carrying E6 and E7 viral oncogenes leads to centrosome amplification (Duensing and Munger, 2002; Riley et al., 2003) . In human breast cancer, however, the relationship between cell cycle checkpoint defects. DNA damage and development of centrosome amplification has not e f been extensively investigated. essential for the maintenance of centrosome homeostasis following DNA damage. In the breast cancer models Go/G 1 S G2/M studied here, inactivation of the p53 pathway also leads to the upregulation of cyclin A, suggesting that control of centrosome duplication may depend on a balance showed that MCF-7 cells exhibited a low level of the wild-type protein, while vMCF-7oNps3 and MDA-MB corresponding increase in the S and G 2 iM phases of the 231 cells showed a high level of mutant p53 expression cell cycle ( Figure If) . These results show that while (Figure la) . Immunofluorescence was performed to partial inhibition of p53 function accelerated both entry label centrioles and pericentriolar material using priinto S phase and the centrosome duplication cycle, mary antibodies against the centrosome proteins centrin centrosome duplication nonetheless remained coordiand pericentrin, respectively. MCF-7 cells showed a nated with DNA replication and cell cycle progression. normal centrosome phenotype with two or four To determine if the complete abrogation of p53 function centrioles according to the phase of the cell cycle may have different effects on centrosome characteristics, (Figure lb, e) . The vMCF-7"'Ps" cells exhibited normal we further analysed centrosome phenotype in the breast centrosomes: however, they showed a higher percentage cancer cell line MDA-MB 231, which carries only of cells with duplicated centrosomes (total of four mutant p53. Immunofluorescence analysis (Figure ld ) centrioles) compared to the parental cell line (Figure lc, showed amplified centrosomes, which were charactere). To determine if the difference in centrosome number ized by supernumerary centrioles and excess pericenwas related to cell cycle progression. we performed triolar material in 56% of the cells. FACS analysis FACS analysis and found that the vMCF- 
MCF-7
cells showing greater than four centrioles after treatment wCFwith HU (Figure 3a middle row, b) . Interestingly, in "these cells, centriole overduplication was not accompanied by a dramatic increase of the centrosome size ( Figure 3c and Table 1 ). However, a striking change in confirmed the immunofluorescence findings. Figure 4 shows representative images of MCF-7 centrosomes, In order to further investigate the role of cyclinicdk following genotoxic stress activity in the development of centrosome amplification following DNA damage, we determined the effect of roscovitine, a potent inhibitor of the cdk activity (Mgbonyebi et al., 1999) , on the level of expression of breast cancer patients due to the generation of diverse key GI/S cell cycle checkpoint regulators and on HUtumor cell phenotypes, which in turn may facilitate the induced centrosome hyperamplification in the MDAdevelopment of chemoresistance and tumor progression MB 231 cell line. Roscovitine treatment resulted in a (Khong and Restifo. 2002: Pinto et al., 2003) . However, decrease in both Rb phosphorylation and cyclin A molecular mechanisms associated with the development expression in HU-treated cells, indicating an effective of genomic instability and aneuploidy are poorly arrest in the progression of the GI/S cell cycle understood in breast cancer. Several studies suggest marrestin tery pogures.io n athat deregulation of the centrosome cycle may lead to machinery (Figure 7a ). Immunofluorescence analysis the development of chromosomal instability through the also demonstrated that roscovitine treatment effectively formation of multipolar mitotic spindles and unequtal reduced centrosome hyperamplification induced by HU (Figure 7b-f , Table 1 ). These experiments demonstrated chromosome segregation (Lingle and Salisbury, 1999 : that in cancer cells lacking p2e expression, it is possible Goepfert et al., 2002 : Kramer et al., 2002 to experimentally block centrosome hyperamplification 2002T Duensing and Mungern p53, Pihan et al., 2003) . through the inhibition of cyctinicdk activity. These
The tumor suppressor gene p53, mutated in more than trosughs futher inhbiatio n ofcycintcdklact n Thes 50% of human cancers (Lane and Benchimol, 1990 ; results further substantiate an interplay between the Levine et al., 1991) , plays an important role in the p53-mediatedmaintenance of centrosome homeostasis since loss of ma function, and cyclin A expression in the maintenance mainten nc of centrosome hom es ts loss o of centrosome homeostasis following genotoxic stress in et3 function can lead to centrosome defects (Fukasawa breast cancer cells. et al., 1996 : Borel et al., 2002 : Tarapore and Fukasawa, 2002 . However, since p53-null mice develop normally and have normal centrosomes in most of their cells, the development of centrosome amplification in this model Discussion may result only after failure of p53 function following genotoxic stress. Furthermore, the cdk/cyclins have also Deregulation of cell cycle checkpoints, development of been implicated in the control of centrosome duplication genomic instability, and aneuploidy are hallmarks of (Hinchcliffe et al., 1999 : Lacey et al., 1999 : Meraldi et al., breast cancer (Anbazhagan et al., 1991 Wenger et al., 1999) and changes in their expression correlate with 1993: Gunther et al., 1997). Genomic instability centrosome amplification (Kronenwett et al., 2003) , represents a major problem in the management of suggesting an interplay between p53 and cdk/cyclin drugs. This process may facilitate the development of tion in cancer, centrosome characteristics were monhigher clonal heterogeneity leading to chemoresistance itored in human breast cancer cell lines with intact or and poor outcome. To overcome the complications abrogated GtiS checkpoint function. We compared the associated with centrosome amplification for this subset behavior of the breast tumor-derived cell lines MCF-7, of breast cancer patients, treatment with cdk inhibitors vMCF -7"N'I", and MDA-MB 231 and determined that in combination with anticancer genotoxic drugs may the progressive loss of p53 function leads to the provide an attractive therapeutic approach. acquisition of increasingly severe centrosome defects following genotoxic stress. MCF-7 cells, which have wild-type p53, arrested the centrosome duplication cycle Materials and methods when DNA damage was introduced by treatment with either HU or DR. In this cell line, activation of the G 1 iS Cell lines cell cycle checkpoint was indicated by an increase of p53
The human breast cancer cell lines (MCF-7 and MDA-MB and p21wA" expression and their nuclear localization, 231) were obtained from ATCC (Manassas. VA, USA) and retinoblastoma hypophosphorylation, and reduction of 2)eotained fro m cC ntana VA. uSand maintained in EMEM medium containing 5mM glutamine.
cyclin A levels. Therefore, in these cells, activation of the 1% penicillin/streptomycin, and 10% FBS at 37"C in 5% CO, GI/S checkpoint in response to genotoxic stress led to atmosphere. MCF-7 cells were supplemented with 20pg inhibition of centrosome overduplication and mainteinsulini'ml, and MCF-7 cells carrying a dominant-negative nance of a normal centrosome phenotype. In contrast.
p53 mutant (vMCF-7`P"') were grown in selection medium DNA damage led to centrosome amplification in containing 500 pgiml G148. vMCF-7I)1N,3 cells. In these cells, the introduced dominant-negative p53 led to weak induction of Generation of dominant-negative p53 clones p2lwA expression. high level of phosphorylated retino-
The pCMV-p53mt135 expression vector (Clontech, Palo Alto, blastoma, and deregulation of cyclin A expression, CA, USA) was used to generate MCF-7 clones carrying a indicating a failure of GiS cell cycle checkpoint dominant-negative p53 mutant that had a G to A conversion activation. Interestingly, in vMCF-7 1Np 53 cells, centroat nucleotide 1017. This mutant, which is characterized by a some amplification was seen only after induction of Val 135 substitution, forms a mixed tetramer with the p53 DNA damage, since in untreated cells the majority of wild-type protein that is unable to activate its downstream centrosomes showed a normal phenotype. MDA-MB targets. without exerting gain of function activity (Harvey 231 cells, which have mutant p53 and displayed et al., 1995) . MCF-7 cells were plated at a density of 3 x 105. amplified centrosomes at the outset, developed a higher After 24h, cells were transfected using Fugene 6 reagent grade of centrosome defect following DNA damage. In (Roche, Indianapolis, IN, USA) following the rnanufacture's these cells, the development of centrosome hIvperampliinstructions. After 48 h, cells were washed in PBS, and were fiathese cells, t dvopment selected over 3 weeks in medium containing 500 pgiml G418. .[ication was also associated with failure of the 61/S cell Colonies derived from single cells were isolated using cloning cycle checkpoint through lack of p 2 lwAI expression, cylinders, followed by limiting dilution. Individual subclones retinoblastoma hyperphosphorylation, and cyclin A were grown to 80% confluence and frozen. The subcellular overexpression. Importantly, centrosome hyperamplifilocalization and expression of the dominant-negative p53 cation in these cells could be blocked by roscovitine, a in MCF-7 clones were confirmed by immunofluorescence potent inhibitor of cyclinicdk activity that is currently and Western blotting analysis. Clone 8 was used for the under clinical trial (Senderowicz, 2003) . Roscovitine experiments described in this study. treatment mimicked a role for p21 in the p53-defective cell line MDA-MB 231 by effectively rescuing GI/S cell Induction of genotoxic stress cycle checkpoint function, which was characterized by To investigate the relationship between centrosome duplicaRb hypophosphorylation and low levels of cyclin A tion and G,/S checkpoint activation, cell lines were plated at a expression. density of 3 x 105. After 48 h, cells were treated with 2 mM HU In conclusion, the findings reported here suggest that or I liM DR to induce DNA damage and analysed at different p53 and cyclin/cdk pathways regulate centrosome time points up to 48 h. Roscovitine (10 ugiml) was also used to homeostasis by ensuring the integrity of the G I/S cell inhibit cdks activity in combination with HU in the MDA-MB cycle checkpoint. Furthermore, they also demonstrate 231 cell line for 48h. that loss of p53 function alone is not sufficient to cause the development of centrosome amplification, but rather
Cell cvle prq/ile failure of the G 1 iS checkpoint activation following For fluorescence-activated cell sorting (FACS) analysis, cell genotoxic stress is required to induce centriole overlines were washed with cold PBS, fixed in 95% ethanol, stained duplication. This mechanismn may play an important with propidium iodide for 30min and analysed by flow role in the development of centrosome amplification cytometry using Facscan by Becton Dickinson (Franklin during breast cancer development. However, these Lakes, NJ, USA). The resulting cell cycle profiles, based on findings also have important clinical implications for 20000 events, were analysed using the ModFit program by the treatment of breast cancer because they suggest that Verity Software House (Topsham, ME, USA were run in 12% SDS PAGE, transferred to PVDF memDarmstadt, Germany). For the staining of centrioles and brane, fixed in 0.25% glutaraldehyde, blocked in 5% nonfat pericentriolar material, we used antibodies against the proteins dry milk and incubated with primary antibodies against the centrin and pericentrin, respectively. Coverslips were washed following proteins: p53 (D07 DAKO A/S). p21W'I. phosthree times in PBS followed by incubation with secondary phoretinoblastoma (Sigma, St Louis. MO. USA). cyclin E and antibodies conjugated with Alexa 488 or Alexa 568 (Molecular cyclin A (Santa Cruz). and I/-actin (Sigma) as loading control. Probes, Eugene, OR, USA), washed three times in PBS and
After washing in Tween-20 buffer, PVDF membranes were finally incubated in DAPI to stain DNA. Immunofluorescence incubated with HRP secondary antibodies (Amersham, Piscatimages were digitally recorded using a Nikon FXA fluoresaway, NJ, USA), and signal was detected using the ECL-plus cence microscope equipped with computer-controlled focus, reagent (Amersham) following the manufacture's instruction. CCD digital camera, and Metamorph TM (Universal Imaging Corp, Downingtown, PA, USA) software. Fields were
Electron microscopv recorded at multiple focal planes and analysed and printed as maximum projections to assure that all centrioles and Cells were fixed in 2% glutaraldehyde in sodium phosphate centrosomal structures were imaged.
buffer, pH 7.2, for 2h, postlixed in osmium tetroxide, dehydrated through an ethanol series, and embedded in Quantitative anal sis of centrosome size and number Spurr's resin. Silver-gold sections were stained in 2% aqueous uranyl acetate and Reynold's lead citrate, observed using a The NIH image J program was used for the quantitative JEOL 1200 EX electron microscope and recorded digitally. analysis of centrosome size. For each cell line and treatment, centrosome area (prm 2 ) was determined by measuring the fluorescence signal for overlaid images of centrin and
